Anti-tumor effects of patritumab-based antibody-drug conjugate (ADC) on HER1 tyrosine kinase inhibitor-resistant lung cancer cells have been recently reported [48], therefore, we compared the character between present anti-HER3 rat mAb and patritumab. Here, ERBB3 is linked to lung cancer.